For its prominent role in tumor progression, AKT has been proposed as a therapeutic target [39], and it also plays a crucial role in TNBC, and its inhibitors have been tested in clinical trials and in combination with first-line chemotherapy for patients [40]. This evidence concerns the gene AKT1 and neoplasm.